{"schema_version":"1.0","type":"article","title":"Presbyopia drop Ryzumvi wins FDA nod, but nobody wants to sell it","url":"https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner-en.md","lang":"en","date":"2026-10-22","publish_at":"2026-10-22T08:00:00+08:00","updated_at":"2026-10-22","category":"商業分析系列","topic":"商業分析系列","tags":["presbyopia eye drops","Ryzumvi","Vizz","Viatris","phentolamine"],"summary":"Past 40 and holding your phone at arm's length? The FDA approved Ryzumvi, the fifth US presbyopia drop, and Viatris immediately said it wants a partner to sell it. The best seller, Vizz, made $1.7M last quarter.","key_points":["Viatris's presbyopia eye drop Ryzumvi will not launch in the US for presbyopia before June 30, 2027; the FDA approved the indication on October 16, 2026, and Viatris said the same day it is exploring a US commercial partner.","The US now has five presbyopia drops (Vuity, Qlosi, Vizz, Yuvezzi, Ryzumvi); the best disclosed quarter belongs to LENZ's Vizz, with $1.7 million in Q2 2026 net product revenue on about 27,000 packs and more than 13,000 prescribers since launch.","In the 545-patient Phase 3 VEGA-3 trial, 27.2% of Ryzumvi users gained three or more lines of near vision 12 hours after dosing on Day 8 versus 11.5% on placebo, with 2.6% headache but 21% conjunctival hyperemia on the label."],"facts":[{"claim":"Ryzumvi presbyopia indication FDA approval announcement date (US Eastern)","value":"2026-10-16","unit":"date","as_of":"2026-10-16","source":"https://www.prnewswire.com/news-releases/viatris-receives-us-fda-approval-for-ryzumvi-for-the-treatment-of-presbyopia-302911593.html"},{"claim":"Ryzumvi presbyopia label: conjunctival hyperemia rate","value":21,"unit":"%","as_of":"2026-10-16","source":"https://www.prnewswire.com/news-releases/viatris-receives-us-fda-approval-for-ryzumvi-for-the-treatment-of-presbyopia-302911593.html"},{"claim":"Ryzumvi presbyopia label: instillation-site irritation rate","value":16,"unit":"%","as_of":"2026-10-16","source":"https://www.prnewswire.com/news-releases/viatris-receives-us-fda-approval-for-ryzumvi-for-the-treatment-of-presbyopia-302911593.html"},{"claim":"VEGA-3 Phase 3 enrollment","value":545,"unit":"people","as_of":"2025-06-26","source":"https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"},{"claim":"VEGA-3 share gaining 3+ lines of near vision, Day 8, 12 h post-dose: phentolamine","value":27.2,"unit":"%","as_of":"2025-06-26","source":"https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"},{"claim":"VEGA-3 share gaining 3+ lines of near vision, Day 8, 12 h post-dose: placebo","value":11.5,"unit":"%","as_of":"2025-06-26","source":"https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"},{"claim":"VEGA-3 share gaining 3+ lines, Day 1, 1 h post-dose: phentolamine vs placebo","value":"20.6% vs 6.1%","unit":"%","as_of":"2025-06-26","source":"https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"},{"claim":"VEGA-3 headache rate","value":2.6,"unit":"%","as_of":"2025-06-26","source":"https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"},{"claim":"CLARITY 2: Vizz share gaining 3 lines at 30 min and 3 h","value":71,"unit":"%","as_of":"2024-06-01","source":"https://lenz-tx.com/?p=649"},{"claim":"CLARITY 2: Vizz share gaining 3 lines at 10 h","value":40,"unit":"%","as_of":"2024-06-01","source":"https://lenz-tx.com/?p=649"},{"claim":"CLARITY program: Vizz placebo-adjusted headache rate","value":7.6,"unit":"%","as_of":"2024-06-01","source":"https://lenz-tx.com/?p=649"},{"claim":"Vizz FDA approval date","value":"2025-07-31","unit":"date","as_of":"2025-07-31","source":"https://www.hcplive.com/view/fda-approves-aceclidine-vizz-for-presbyopia-in-adults"},{"claim":"Vizz net product revenue, Q2 2026","value":1.7,"unit":"USD million","as_of":"2026-06-30","source":"https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"},{"claim":"Vizz packs sold, Q2 2026","value":27000,"unit":"packs","as_of":"2026-06-30","source":"https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"},{"claim":"Vizz cumulative prescribers through Q2 2026","value":"13,000+","unit":"people","as_of":"2026-06-30","source":"https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"},{"claim":"LENZ Therapeutics net loss, Q2 2026","value":31.9,"unit":"USD million","as_of":"2026-06-30","source":"https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"},{"claim":"LENZ Therapeutics cash and marketable securities, June 30, 2026","value":220,"unit":"USD million","as_of":"2026-06-30","source":"https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"},{"claim":"Tenpoint Series B and credit facility to launch Yuvezzi","value":235,"unit":"USD million","as_of":"2026-01-29","source":"https://pharmaphorum.com/news/tenpoint-eyes-presbyopia-drug-launch-after-fda-nod"},{"claim":"AbbVie 2022 impairment charge linked to Vuity (per pharmaphorum)","value":770,"unit":"USD million","as_of":"2026-01-29","source":"https://pharmaphorum.com/news/tenpoint-eyes-presbyopia-drug-launch-after-fda-nod"},{"claim":"US presbyopia population cited by AbbVie at Vuity approval","value":128,"unit":"million people","as_of":"2021-10-29","source":"https://news.abbvie.com/2021-10-29-U-S-Food-and-Drug-Administration-Approves-VUITY-TM-pilocarpine-HCI-ophthalmic-solution-1-25-,-the-First-and-Only-Eye-Drop-to-Treat-Presbyopia-Age-Related-Blurry-Near-Vision"},{"claim":"Viatris upfront payment for global Nyxol (phentolamine) license, Nov 2022","value":35,"unit":"USD million","as_of":"2022-11-07","source":"https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-22-040303/brhc10043812_ex99-1.htm"},{"claim":"Viatris total for Oyster Point and Famy acquisitions, Jan 2023","value":750,"unit":"USD million","as_of":"2023-01-05","source":"https://www.dcatvci.org/top-industry-news/viatris-completes-750-m-acquisition-of-two-ophthalmology-companies/"},{"claim":"People in Taiwan who have had laser vision correction (per Dr. Lu Da-wen)","value":"1 million+","unit":"people","as_of":"2026-02-07","source":"https://health.ltn.com.tw/article/breakingnews/5335642"},{"claim":"Vizz Q4 2025 revenue (per pharmaphorum)","value":1.6,"unit":"USD million","as_of":"2025-12-31","source":"https://pharmaphorum.com/news/tenpoint-eyes-presbyopia-drug-launch-after-fda-nod"},{"claim":"Vizz Q1 2026 net product revenue (six-month total minus Q2)","value":1.65,"unit":"USD million","as_of":"2026-03-31","source":"https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"}],"sections":["01 | Why can a single drop make reading easier?","02 | One drop at bedtime: how much better is the morning?","03 | The first drop stumbled, and the second sells slowly","04 | Viatris already has an eye-care sales team. Why look for a partner?","05 | Taiwan: none approved yet, and a myopia problem","References"],"references":[{"title":"Viatris Receives U.S. FDA Approval for RYZUMVI for the Treatment of Presbyopia","source":"Viatris (PR Newswire","date":"2026-10-16","url":"https://www.prnewswire.com/news-releases/viatris-receives-us-fda-approval-for-ryzumvi-for-the-treatment-of-presbyopia-302911593.html"},{"title":"Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia","source":"Opus Genetics (Yahoo Finance","date":"2026-10-16","url":"https://finance.yahoo.com/healthcare/articles/opus-genetics-announces-fda-approval-160000544.html"},{"title":"FDA Approves RYZUMVI for Presbyopia; Viatris Seeks Commercial Partner","source":"Clinical Trial Vanguard","date":"2026-10-17","url":"https://www.clinicaltrialvanguard.com/news/fda-approves-ryzumvi-for-presbyopia-viatris-seeks-commercial-partner/"},{"title":"Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint","source":"Opus Genetics","date":"2025-06-26","url":"https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"},{"title":"LENZ Therapeutics Reports Second Quarter 2026 Financial Results","source":"LENZ Therapeutics (StockTitan","date":"2026-08-11","url":"https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"},{"title":"FDA Approves Aceclidine (VIZZ) for Presbyopia in Adults","source":"HCPLive","date":"2025-07-31","url":"https://www.hcplive.com/view/fda-approves-aceclidine-vizz-for-presbyopia-in-adults"},{"title":"LENZ Therapeutics announces results from Phase 3 CLARITY study","source":"LENZ Therapeutics","date":"2024-06-01","url":"https://lenz-tx.com/?p=649"},{"title":"Tenpoint eyes presbyopia drug launch after FDA nod","source":"pharmaphorum","date":"2026-01-29","url":"https://pharmaphorum.com/news/tenpoint-eyes-presbyopia-drug-launch-after-fda-nod"},{"title":"Tenpoint Therapeutics Announces FDA Approval of YUVEZZI","source":"Tenpoint Therapeutics (Business Wire","date":"2026-01-28","url":"https://www.businesswire.com/news/home/20260128284402/en/Tenpoint-Therapeutics-Ltd.-Announces-FDA-Approval-of-YUVEZZI-the-First-and-Only-Combination-Eye-Drop-Approved-to-Treat-Presbyopia"},{"title":"U.S. FDA Approves VUITY, the First and Only Eye Drop to Treat Presbyopia","source":"AbbVie","date":"2021-10-29","url":"https://news.abbvie.com/2021-10-29-U-S-Food-and-Drug-Administration-Approves-VUITY-TM-pilocarpine-HCI-ophthalmic-solution-1-25-,-the-First-and-Only-Eye-Drop-to-Treat-Presbyopia-Age-Related-Blurry-Near-Vision"},{"title":"AbbVie Form 10-Q for the quarter ended September 30, 2022","source":"U.S. SEC","date":"2022-09-30","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115222000045/abbv-20220930.htm"},{"title":"Ocuphire Pharma Enters Global License Agreement with Viatris for Nyxol","source":"Ocuphire Pharma (SEC 8-K Exhibit 99.1","date":"2022-11-07","url":"https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-22-040303/brhc10043812_ex99-1.htm"},{"title":"Viatris Completes $750-M Acquisition of Two Ophthalmology Companies","source":"DCAT Value Chain Insights","date":"2023-01-05","url":"https://www.dcatvci.org/top-industry-news/viatris-completes-750-m-acquisition-of-two-ophthalmology-companies/"},{"title":"Presbyopia eye drops may launch next year (in Chinese","source":"EBC News","date":"2026-10-12","url":"https://news.ebc.net.tw/news/health/575361"},{"title":"New presbyopia drop cleared by FDA; why Taiwan can't buy it (in Chinese","source":"Liberty Times Health","date":"2026-02-07","url":"https://health.ltn.com.tw/article/breakingnews/5335642"}],"images":[{"alt":"How presbyopia drops work: most tighten the iris sphincter, Ryzumvi relaxes the dilator","url":"https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner-en/figure-01.png"},{"alt":"Vizz in Q2 2026: 13,000+ prescribers, $1.7M net product revenue","url":"https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner-en/figure-02.png"},{"alt":"Timeline of five US presbyopia drops: Vuity, Qlosi, Vizz, Yuvezzi, Ryzumvi","url":"https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner-en/figure-03.png"},{"alt":"Taiwan and presbyopia drops: none approved, earliest arrival 2027, over one million post-laser patients","url":"https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-22）。Presbyopia drop Ryzumvi wins FDA nod, but nobody wants to sell it。https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}